CD8 Technology signs letter of intent for Tevogen Bio's cell therapy manufacturing facility

CD8 Technology Services LLC signed a letter of intent for a facility to support Tevogen Bio's cell therapy manufacturing, marking the first phase of up to $50 million commitment.

“In-house manufacturing is critical to our operational efficiency, and with 74% insider ownership, we place the highest value on business discipline.”business.thepilotnews.com

• 1 source
• business.thepilotnews.comUser | thepilotnews.com - CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million CommitmentTevogen Bio IncApr 30, 2025

Summarized from public sources; check the original articles before acting on it.